Although acute toxicity studies in animals are an indispensable prerequisite for the realisation of clinical trials in humans, these can only be projected to humans to a limited extent, and thus are scientifically problematic and ethically questionable. Therefore, the international regulat ... more
Dr. Reiner Claß
Pharmacelsus GmbH
received his doctorate in biology at Saarland University, with a subsequent post-doctoral period at the Wistar Institute in Philadelphia (USA). In 1992, he was appointed faculty member of Drexel University (Philadelphia, USA), where he served as Director of the Flow Cytometry Core Facility and headed the Oncology Research Laboratory in the Department of Radiation Oncology. In 2001, he returned to Germany and assumed the position of CSO at SymbioTec GmbH, where he was responsible for the preclinical and clinical development of biotechnologically derived active ingredients. Today, he manages the “Target Finding & Biological Profiling“ department at Pharmacelsus.